Clinical trial

A Study of 2 Doses of MAP0010 in Adult Asthmatics

NCT00554970

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-11-01

PhasePHASE2

Study timeline

Study start (unknown)2007-11-01Date precision: month

Registry last updated2014-01-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

MAP0010 low doseDRUG

MAP0010 high doseDRUG

Budesonide inhalation suspension 0.25mgDRUG

Budesonide inhalation suspension 0.5mgDRUG

Sponsors & collaborators

Allerganlead sponsor

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergancollaborator

Mapped research locations

Long BeachCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00554970 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.